Preferred Label : Osteogenesis imperfecta, type XIII;
Symbol : OI13;
CISMeF acronym : OI13;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Oi, type XIII;
Description : Osteogenesis imperfecta (OI) is a connective tissue disorder characterized by bone
fragility and low bone mass. Due to considerable phenotypic variability, Sillence
et al. (1979) developed a classification of OI subtypes based on clinical features
and disease severity: OI type I, with blue sclerae (166200); perinatal lethal OI type
II, also known as congenital OI (166210); OI type III, a progressively deforming form
with normal sclerae (259420); and OI type IV, with normal sclerae (166220). Most cases
of OI are autosomal dominant with mutations in 1 of the 2 genes that code for type
I collagen alpha chains, COL1A1 (120150) and COL1A2 (120160). Martinez-Glez et al.
(2012) described osteogenesis imperfecta type XIII, an autosomal recessive form of
the disorder characterized by normal teeth, faint blue sclerae, severe growth deficiency,
borderline osteoporosis, and an average of 10 to 15 fractures a year affecting both
upper and lower limbs and with severe bone deformity.;
Inheritance : Autosomal recessive;
Molecular basis : Caused by mutation in the bone morphogenetic protein-1 gene (BMP1, 112264.0001);
Laboratory abnormalities : Normal calcium level; Normal phosphate level; Normal to slightly high alkaline phosphatase; Low procollagen 1 C-peptide (in some patients); High deoxypyridinoline/creatinine (in some patients);
Prefixed ID : #614856;
Origin ID : 614856;
UMLS CUI : C3553887;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
Not associated HPO term(s)
ORDO concept(s)
Semantic type(s)